{
    "clinical_study": {
        "@rank": "10021", 
        "arm_group": [
            {
                "arm_group_label": "ALN-AT3SC", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Sterile Normal Saline (0.9% NaCl)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of\n      ALN-AT3SC in healthy volunteers and Hemophilia A or B patients."
        }, 
        "brief_title": "A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hemophilia A", 
            "Hemophilia B"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemophilia B", 
                "Hemophilia A"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Part A (SAD phase) inclusion:\n\n          -  Healthy adult males aged 18 to 40 years inclusive at Screening.\n\n          -  Subjects with adequate complete blood counts and liver function tests.\n\n          -  Willing to provide written informed consent and willing to comply with study\n             requirements.\n\n        Part B (MAD phase) inclusion:\n\n          -  Adult male hemophilia patients aged 18 to 65 years inclusive at Screening.\n\n          -  Patients with adequate complete blood counts and liver function tests.\n\n          -  Patients with moderate or severe, clinically stable hemophilia A or B (Factor VIII or\n             Factor IX \u22645%).\n\n          -  Willing to provide written informed consent and willing to comply with study\n             requirements\n\n        Exclusion Criteria:\n\n        Part A (SAD phase) exclusion:\n\n          -  Subjects with a personal history and/or family history of venous thromboembolism\n             (VTE)\n\n          -  Subjects with a known co-existing thrombophilic disorder\n\n          -  Subjects with a history of multiple drug allergies or history of allergic reaction to\n             an oligonucleotide or GalNAc.\n\n          -  Subjects with a history of serious mental illness that includes, but is not limited\n             to schizophrenia, bipolar disorder, severe depression requiring hospitalization or\n             pharmacological intervention.\n\n          -  Subjects who have a clinically relevant history or presence of cardiovascular,\n             respiratory, gastrointestinal, renal, hematological, lymphatic, neurological,\n             musculoskeletal, genitourinary, immunological including osteoarthritis and other\n             inflammatory diseases, dermatological including rash, eczema, dermatitis, or\n             connective tissue diseases or disorders.\n\n        Part B (MAD phase) exclusion:\n\n          -  Patients with a history of serious mental illness, that includes, but is not limited\n             to schizophrenia, bipolar disorder, severe depression requiring hospitalization or\n             pharmacological intervention.\n\n          -  Patients who have a clinically relevant history or presence of cardiovascular,\n             respiratory, gastrointestinal, renal, neurological, inflammatory or other diseases\n             that in the judgment of the investigator precludes their participation in the study.\n\n          -  Patients with a known co-existing thrombophilic disorder\n\n          -  Patients with a history of multiple drug allergies or history of allergic reaction to\n             an oligonucleotide or GalNAc.\n\n          -  Patients who are known to be HIV positive and have a CD4 count <400 cells/\u03bcL"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035605", 
            "org_study_id": "ALN-AT3SC-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "ALN-AT3SC", 
                "description": "Ascending doses of ALN-AT3SC by subcutaneous (sc) injection", 
                "intervention_name": "ALN-AT3SC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sterile Normal Saline (0.9% NaCl)", 
                "description": "Calculated volume to match active comparator", 
                "intervention_name": "Sterile Normal Saline (0.9% NaCl)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Clinical Trial Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia)", 
        "overall_contact": {
            "last_name": "Alnylam Clinical Trials Hotline Call for Complete Site List", 
            "phone": "617-575-7400"
        }, 
        "overall_contact_backup": {
            "last_name": "Alnylam Clinical Trials Hotline Call for Complete Site List", 
            "phone": "1-866-330-0326"
        }, 
        "overall_official": {
            "affiliation": "Alnylam Pharmaceuticals", 
            "last_name": "Benny Sorensen, MD PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The safety of ALN-AT3SC evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and AEs leading to study drug discontinuation.", 
            "safety_issue": "Yes", 
            "time_frame": "Part A (SAD phase): through day 56; Part B (MAD) phase: through Day 70"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035605"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The pharmacokinetics (PK) of ALN-AT3SC as characterized by plasma PK profiles and urine samples.", 
                "safety_issue": "No", 
                "time_frame": "Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70"
            }, 
            {
                "measure": "The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma AT levels.", 
                "safety_issue": "No", 
                "time_frame": "Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70"
            }, 
            {
                "measure": "The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma TG.", 
                "safety_issue": "No", 
                "time_frame": "Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70"
            }
        ], 
        "source": "Alnylam Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alnylam Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}